Details of the Drug

General Information of Drug (ID: DMVS9WQ)

Drug Name
Nitisinone
Synonyms
Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
Indication
Disease Entry ICD 11 Status REF
Hereditary tyrosinemia type 1 5C50.11 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 329.23
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 54 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.0748 micromolar/kg/day [5]
Chemical Identifiers
Formula
C14H10F3NO5
IUPAC Name
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
Canonical SMILES
C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
InChI
InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2
InChIKey
OUBCNLGXQFSTLU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
115355
ChEBI ID
CHEBI:50378
CAS Number
104206-65-7
DrugBank ID
DB00348
TTD ID
D0V1UW
ACDINA ID
D00474

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hydroxyphenylpyruvate dioxygenase (HPD) TT8DSFC HPPD_HUMAN Inhibitor [6], [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nitisinone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Isotretinoin DM4QTBN Moderate Decreased metabolism of Nitisinone caused by Isotretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [12]
Metreleptin DM1NOEK Moderate Increased metabolism of Nitisinone caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Glibenclamide DM8JXPZ Moderate Decreased metabolism of Nitisinone caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Tolazamide DMIHRNA Moderate Decreased metabolism of Nitisinone caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Pioglitazone DMKJ485 Moderate Increased metabolism of Nitisinone caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Nateglinide DMLK2QH Moderate Decreased metabolism of Nitisinone caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Acetohexamide DMR6N7H Moderate Decreased metabolism of Nitisinone caused by Acetohexamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Nitisinone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Arn-509 DMT81LZ Moderate Increased metabolism of Nitisinone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Mitotane DMU1GX0 Moderate Increased metabolism of Nitisinone caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [12]
Nifedipine DMSVOZT Moderate Decreased metabolism of Nitisinone caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [12]
Marinol DM70IK5 Moderate Decreased metabolism of Nitisinone caused by Marinol mediated inhibition of CYP450 enzyme. Anorexia nervosa [6B80] [12]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Nitisinone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [12]
Voriconazole DMAOL2S Moderate Decreased metabolism of Nitisinone caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [12]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nitisinone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [12]
Montelukast DMD157S Moderate Decreased metabolism of Nitisinone caused by Montelukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [13]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Nitisinone caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [12]
Oritavancin DM28D05 Moderate Increased metabolism of Nitisinone caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Nitisinone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nitisinone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Nitisinone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Meropenem DM62UHC Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Meropenem. Bacterial infection [1A00-1C4Z] [14]
Sulfamethoxazole DMB08GE Moderate Decreased metabolism of Nitisinone caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Nitisinone caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Nitisinone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Nitisinone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nitisinone caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Tucatinib DMBESUA Moderate Decreased metabolism of Nitisinone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Palbociclib DMD7L94 Moderate Decreased metabolism of Nitisinone caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Nitisinone caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Nitisinone caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [12]
Micafungin DM6Y3AN Moderate Decreased metabolism of Nitisinone caused by Micafungin mediated inhibition of CYP450 enzyme. Candidosis [1F23] [12]
Secobarbital DM14RF5 Moderate Increased metabolism of Nitisinone caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [12]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Nitisinone caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [12]
Thiopental DMGP8AX Moderate Increased metabolism of Nitisinone caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [12]
Mifepristone DMGZQEF Moderate Decreased metabolism of Nitisinone caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [16]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Nitisinone caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [12]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Nitisinone caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [12]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Nitisinone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [12]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nitisinone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [12]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nitisinone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [12]
Aprepitant DM053KT Moderate Decreased metabolism of Nitisinone caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Sertraline DM0FB1J Moderate Decreased metabolism of Nitisinone caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Nitisinone caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Nitisinone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Paroxetine DM5PVQE Moderate Decreased metabolism of Nitisinone caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Doxepin DMPI98T Moderate Decreased metabolism of Nitisinone caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Griseofulvin DMK54YG Moderate Increased metabolism of Nitisinone caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [12]
Primidone DM0WX6I Moderate Decreased metabolism of Nitisinone caused by Primidone mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Felbamate DM1V5ZS Moderate Increased metabolism of Nitisinone caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Nitisinone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Cenobamate DMGOVHA Moderate Increased metabolism of Nitisinone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nitisinone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Nitisinone caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Rufinamide DMWE60C Moderate Increased metabolism of Nitisinone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Phenobarbital DMXZOCG Moderate Decreased metabolism of Nitisinone caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Carbamazepine DMZOLBI Moderate Increased metabolism of Nitisinone caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Nitisinone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Suprofen DMKXJZ7 Moderate Decreased metabolism of Nitisinone caused by Suprofen mediated inhibition of CYP450 enzyme. Eye anterior segment structural developmental anomaly [LA11] [12]
Mefenamic acid DMK7HFI Moderate Decreased metabolism of Nitisinone caused by Mefenamic acid mediated inhibition of CYP450 enzyme. Female pelvic pain [GA34] [12]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nitisinone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [12]
Itraconazole DMCR1MV Moderate Decreased metabolism of Nitisinone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [12]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Nitisinone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [12]
Cimetidine DMH61ZB Moderate Decreased metabolism of Nitisinone caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [12]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Nitisinone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [12]
Furosemide DMMQ8ZG Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Furosemide. Heart failure [BD10-BD1Z] [14]
Boceprevir DMBSHMF Moderate Decreased metabolism of Nitisinone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
Telaprevir DMMRV29 Moderate Decreased metabolism of Nitisinone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Nitisinone caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Rifampin DMA8J1G Moderate Increased metabolism of Nitisinone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Rifapentine DMCHV4I Moderate Increased metabolism of Nitisinone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Delavirdine DM3NF5G Moderate Decreased metabolism of Nitisinone caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Efavirenz DMC0GSJ Moderate Increased metabolism of Nitisinone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Saquinavir DMG814N Moderate Decreased metabolism of Nitisinone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Etravirine DMGV8QU Moderate Decreased metabolism of Nitisinone caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Didanosine DMI2QPE Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [14]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Nitisinone caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Darunavir DMN3GCH Moderate Decreased metabolism of Nitisinone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Atazanavir DMSYRBX Moderate Decreased metabolism of Nitisinone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Nitisinone caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [16]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Nitisinone caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [12]
Losartan DM72JXH Moderate Decreased metabolism of Nitisinone caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Levamlodipine DM92S6N Moderate Decreased metabolism of Nitisinone caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Verapamil DMA7PEW Moderate Decreased metabolism of Nitisinone caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Amlodipine DMBDAZV Moderate Decreased metabolism of Nitisinone caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Irbesartan DMTP1DC Moderate Decreased metabolism of Nitisinone caused by Irbesartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Conivaptan DM1V329 Moderate Decreased metabolism of Nitisinone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [19]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Nitisinone caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [12]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Nitisinone caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [20]
Lesinurad DMUR64T Moderate Decreased metabolism of Nitisinone caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [21]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nitisinone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [12]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Nitisinone caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [12]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nitisinone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [12]
Ramelteon DM7IW9J Moderate Decreased metabolism of Nitisinone caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [12]
Methotrexate DM2TEOL Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Methotrexate. Leukaemia [2A60-2B33] [14]
Crizotinib DM4F29C Moderate Decreased metabolism of Nitisinone caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Brigatinib DM7W94S Moderate Increased metabolism of Nitisinone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [23]
Ceritinib DMB920Z Moderate Decreased metabolism of Nitisinone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Osimertinib DMRJLAT Moderate Decreased metabolism of Nitisinone caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nitisinone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Idelalisib DM602WT Moderate Decreased metabolism of Nitisinone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [24]
IPI-145 DMWA24P Moderate Decreased metabolism of Nitisinone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [12]
Clofarabine DMCVJ86 Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Clofarabine. Mature B-cell lymphoma [2A85] [14]
Vemurafenib DM62UG5 Moderate Increased metabolism of Nitisinone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [12]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nitisinone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Danazol DML8KTN Moderate Decreased metabolism of Nitisinone caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [12]
Exjade DMHPRWG Moderate Decreased metabolism of Nitisinone caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [25]
Flibanserin DM70DTN Moderate Decreased metabolism of Nitisinone caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [12]
Siponimod DM2R86O Major Decreased metabolism of Nitisinone caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [16]
Rifabutin DM1YBHK Moderate Increased metabolism of Nitisinone caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [12]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nitisinone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Nilotinib DM7HXWT Moderate Decreased metabolism of Nitisinone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [26]
Imatinib DM7RJXL Moderate Decreased metabolism of Nitisinone caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [27]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nitisinone caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Modafinil DMYILBE Minor Increased metabolism of Nitisinone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [28]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nitisinone caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [12]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Nitisinone caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [12]
Diclofenac DMPIHLS Moderate Decreased metabolism of Nitisinone caused by Diclofenac mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [12]
Naproxen DMZ5RGV Moderate Decreased metabolism of Nitisinone caused by Naproxen mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [12]
Olaparib DM8QB1D Moderate Decreased metabolism of Nitisinone caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [12]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nitisinone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [12]
Piroxicam DMTK234 Moderate Decreased metabolism of Nitisinone caused by Piroxicam mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [12]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Nitisinone caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [12]
Abametapir DM2RX0I Moderate Decreased metabolism of Nitisinone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [29]
Lefamulin DME6G97 Moderate Decreased metabolism of Nitisinone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [30]
Prednisone DM2HG4X Moderate Increased metabolism of Nitisinone caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [12]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Nitisinone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [31]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Nitisinone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [12]
Enzalutamide DMGL19D Moderate Increased metabolism of Nitisinone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [12]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Nitisinone caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [12]
Bosentan DMIOGBU Moderate Decreased metabolism of Nitisinone caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [32]
Meloxicam DM2AR7L Moderate Decreased metabolism of Nitisinone caused by Meloxicam mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Baricitinib DM4ONW5 Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Baricitinib. Rheumatoid arthritis [FA20] [14]
Celecoxib DM6LOQU Moderate Decreased metabolism of Nitisinone caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Flurbiprofen DMGN4BY Moderate Decreased metabolism of Nitisinone caused by Flurbiprofen mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Dexamethasone DMMWZET Moderate Increased metabolism of Nitisinone caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Nafcillin DMN9RPO Moderate Increased metabolism of Nitisinone caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Nitisinone caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [33]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nitisinone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [12]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nitisinone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [20]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nitisinone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Cyclophosphamide DM4O2Z7 Moderate Decreased metabolism of Nitisinone caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Armodafinil DMGB035 Minor Increased metabolism of Nitisinone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
LEE011 DMMX75K Moderate Decreased metabolism of Nitisinone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nitisinone caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [20]
Warfarin DMJYCVW Moderate Decreased metabolism of Nitisinone caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [12]
As-1670542 DMV05SW Moderate Decreased metabolism of Nitisinone caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [12]
Brilinta DMBR01X Moderate Decreased metabolism of Nitisinone caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [12]
Tolbutamide DM02AWV Moderate Decreased metabolism of Nitisinone caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [12]
Sitagliptin DMGDKXN Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Sitagliptin. Type 2 diabetes mellitus [5A11] [14]
Chlorpropamide DMPHZQE Moderate Decreased metabolism of Nitisinone caused by Chlorpropamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [12]
Elagolix DMB2C0E Moderate Increased metabolism of Nitisinone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [12]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Nitisinone caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [12]
Ganciclovir DM1MBYQ Moderate Decreased clearance of Nitisinone due to the transporter inhibition by Ganciclovir. Virus infection [1A24-1D9Z] [14]
⏷ Show the Full List of 154 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nitisinone 10 mg tablet 10 mg Oral Tablet Oral
Nitisinone 2 mg tablet 2 mg Oral Tablet Oral
Nitisinone 5 mg tablet 5 mg Oral Tablet Oral
Nitisinone 10 mg capsule 10 mg Oral Capsule Oral
Nitisinone 2 mg capsule 2 mg Oral Capsule Oral
Nitisinone 20 mg capsule 20 mg Oral Capsule Oral
Nitisinone 5 mg capsule 5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6834).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021232.
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.
7 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6.
8 Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
11 Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13.
12 Canadian Pharmacists Association.
13 Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
14 Product Information. Orfadin (nitisinone). Orphan Pharmaceuticals USA, Inc, Nashville, TN.
15 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
18 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
19 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
22 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
24 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
25 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
28 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
29 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
30 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
31 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
32 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
33 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.